thiscart22 cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 23, 2020 (NCT04601181)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05106946 | Phase 1 | Oct 25, 2021 | Fundamenta Therapeutics, Ltd., Xuzhou Medical University |
| NCT04601181 | Phase 1 | Oct 23, 2020 | Anhui Province Cancer Hospital, Fundamenta Therapeutics, Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fundamenta Therapeutics, Ltd. | For profit | 2 | 2 | 1 | 2020 |
| Anhui Province Cancer Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Xuzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1